Development of Novel 4-Arylpyridin-2-one and 6-Arylpyrimidin-4-one Positive Allosteric Modulators of the M


Journal

ChemMedChem
ISSN: 1860-7187
Titre abrégé: ChemMedChem
Pays: Germany
ID NLM: 101259013

Informations de publication

Date de publication:
08 01 2021
Historique:
received: 21 07 2020
pubmed: 28 8 2020
medline: 18 9 2021
entrez: 28 8 2020
Statut: ppublish

Résumé

This study investigated the structure-activity relationships of 4-phenylpyridin-2-one and 6-phenylpyrimidin-4-one M

Identifiants

pubmed: 32851779
doi: 10.1002/cmdc.202000540
doi:

Substances chimiques

4-phenylpyridin-2-one 0
Pyridones 0
Receptor, Muscarinic M1 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

216-233

Subventions

Organisme : Wellcome Trust
ID : 201529Z16Z
Pays : United Kingdom

Informations de copyright

© 2020 Wiley-VCH GmbH.

Références

M. P. Caulfield, N. J. M. Birdsall, Pharmacol. Rev. 1998, 50, 279-290.
 
R. M. Eglen, Prog. Med. Chem. 2005, 43, 105-136;
R. M. Eglen, Auton. Autacoid Pharmacol. 2006, 26, 219-233;
J. Wess, Muscarinic Acetylcholine Receptors, Vol. 1, Wiley, 2007, pp. 147-192.
 
M. P. Caulfield, Pharmacol. Ther. 1993, 58, 319-379;
N. M. Nathanson, Proc. Natl. Acad. Sci. USA 2000, 97, 6245-6247.
J. Wess, Annu.Rev. Pharmacol. Toxicol. 2004, 44, 423-450.
A. Schiavone, A. Sagrada, R. Micheletti, A. Giachetti, Br. J. Pharmacol. 1988, 94, 566-572.
O. Soukup, M. Winder, U. K. Killi, V. Wsol, D. Jun, K. Kuca, G. Tobin, Curr. Neuropharmacol. 2017, 15, 637-653.
 
“Cholinesterase Inhibitors for Alzheimer's Disease”, J. Birks, Cochrane Database Syst. Rev., 2006, p. CD005593;
J. Wess, R. M. Eglen, D. Gautam, Nat. Rev. Drug Discovery 2007, 6, 721-733;
D. M. Thal, B. Sun, D. Feng, V. Nawaratne, K. Leach, C. C. Felder, M. G. Bures, D. A. Evans, W. I. Weis, P. Bachhawat, T. S. Kobilka, P. M. Sexton, B. K. Kobilka, A. Christopoulos, Nature 2016, 531, 335-340.
 
A. Christopoulos, Nat. Rev. Drug Discovery 2002, 1, 198-210;
P. J. Conn, C. W. Lindsley, J. Meiler, C. M. Niswender, Nat. Rev. Drug Discovery 2014, 13, 692-708;
M. Decker, U. Holzgrabe, MedChemComm 2012, 3, 752-762;
P. J. Conn, A. Christopoulos, C. W. Lindsley, Nat. Rev. Drug Discovery 2009, 8, 41-54.
L. Ma, M. Seager, M. Wittmann, M. Jacobson, D. Bickel, M. Burno, K. Jones, V. K. Graufelds, G. Xu, M. Pearson, A. McCampbell, R. Gaspar, P. Shughrue, A. Danziger, C. Regan, R. Flick, D. Pascarella, S. Garson, S. Doran, C. Kreatsoulas, L. Veng, C. W. Lindsley, W. Shipe, S. Kuduk, C. Sur, G. Kinney, G. R. Seabrook, W. J. Ray, Proc. Natl. Acad. Sci. USA 2009, 106, 15950-15955, S15950/15951-S15950/15959.
 
S. N. Mistry, M. Jörg, H. Lim, N. B. Vinh, P. M. Sexton, B. Capuano, A. Christopoulos, J. R. Lane, P. J. Scammells, J. Med. Chem. 2016, 59, 388-409;
S. N. Mistry, H. Lim, M. Jörg, B. Capuano, A. Christopoulos, J. R. Lane, P. J. Scammells, ACS Chem. Neurosci. 2016, 7, 647-661;
J. C. C. Dallagnol, E. Khajehali, E. T. van der Westhuizen, M. Jörg, C. Valant, A. G. Gonçalves, B. Capuano, A. Christopoulos, P. J. Scammells, J. Med. Chem. 2018, 61, 2875-2894;
A. Abdul-Ridha, J. R. Lane, S. N. Mistry, L. López, P. M. Sexton, P. J. Scammells, A. Christopoulos, M. Canals, J. Biol. Chem. 2014;
A. Abdul-Ridha, L. Lopez, P. Keov, D. M. Thal, S. N. Mistry, P. M. Sexton, J. R. Lane, M. Canals, A. Christopoulos, J. Biol. Chem. 2014, 289, 6067-6079;
S. N. Mistry, C. Valant, P. M. Sexton, B. Capuano, A. Christopoulos, P. J. Scammells, J. Med. Chem. 2013, 56, 5151-5172;
M. A. Brodney, J. E. Davoren, M. R. Garnsey, L. Zhang, S. V. O′Neil, Preparation of Pyridine-2-carboxamide Derivatives as Muscarinic M1 Receptor Positive Allosteric Modulators, Pfizer, USA . 2016, p. 174pp;
J. E. Davoren, M. Garnsey, B. Pettersen, M. A. Brodney, J. R. Edgerton, J.-P. Fortin, S. Grimwood, A. R. Harris, S. Jenkinson, T. Kenakin, J. T. Lazzaro, C.-W. Lee, S. M. Lotarski, L. Nottebaum, S. V. O′Neil, M. Popiolek, S. Ramsey, S. J. Steyn, C. A. Thorn, L. Zhang, D. Webb, J. Med. Chem. 2017, 60, 6649-6663;
J. E. Davoren, C.-W. Lee, M. Garnsey, M. A. Brodney, J. Cordes, K. Dlugolenski, J. R. Edgerton, A. R. Harris, C. J. Helal, S. Jenkinson, G. W. Kauffman, T. P. Kenakin, J. T. Lazzaro, S. M. Lotarski, Y. Mao, D. M. Nason, C. Northcott, L. Nottebaum, S. V. O′Neil, B. Pettersen, M. Popiolek, V. Reinhart, R. Salomon-Ferrer, S. J. Steyn, D. Webb, L. Zhang, S. Grimwood, J. Med. Chem. 2016, 59, 6313-6328;
J. M. Rook, M. Abe, H. P. Cho, K. D. Nance, V. B. Luscombe, J. J. Adams, J. W. Dickerson, D. H. Remke, P. M. Garcia-Barrantes, D. W. Engers, J. L. Engers, S. Chang, J. J. Foster, A. L. Blobaum, C. M. Niswender, C. K. Jones, P. J. Conn, C. W. Lindsley, ACS Chem. Neurosci. 2017, 8, 866-883;
J. D. Panarese, H. P. Cho, J. J. Adams, K. D. Nance, P. M. Garcia-Barrantes, S. Chang, R. D. Morrison, A. L. Blobaum, C. M. Niswender, S. R. Stauffer, P. J. Conn, C. W. Lindsley, Bioorg. Med. Chem. Lett. 2016, 26, 3822-3825;
C. W. Lindsley, P. J. Conn, S. R. Stauffer, J. D. Panarese, Substituted 1-Benzylquinoxalin-2(1H)-one Analogs as Positive Allosteric Modulators of Muscarinic Acetylcholine Receptor M1, Vanderbilt University, USA. 2014, p. 208pp;
C. W. Lindsley, P. J. Conn, S. R. Stauffer, J. D. Panarese, Quinazolinone and Pyridopyrimidinone Derivatives as Positive Allosteric Modulators of Muscarinic Acetylcholine Receptor M1 and Their Preparation and Use for the Treatment of Neurological and Psychiatric Disorders, Vanderbilt University, USA. 2014, p. 225;
C. W. Lindsley, P. J. Conn, D. W. Engers, K. A. Bollinger, J. L. Engers, Preparation of Substituted Thienopyridine, Pyrrolopyridine and Pyrazolopyridine Analogs as Positive Allosteric Modulators of Muscarinic Acetylcholine Receptor M1, Vanderbilt University, USA . 2017, p. 184;
B. J. Melancon, J. C. Tarr, J. D. Panarese, M. R. Wood, C. W. Lindsley, Drug Discovery Today 2013, 18, https://doi.org/10.1016/j.drudis.2013.09.005.
 
R. V. Pustovit, M. Ringuet, S. Diwakarla, X.-Y. Chai, R. M. McQuade, J. B. Furness, R. V. Pustovit, M. Ringuet, S. Diwakarla, X.-Y. Chai, R. M. McQuade, J. B. Furness, Y. Itomi, Y. Tsukimi, Neurogenetics 2019, 31, e13692;
S. Sasaki, Y. Asano, H. Maezaki, A. Sato, Preparation of Heterocyclic Compound as Cholinergic Muscarinic M1 Receptor Positive Allosteric Modulator (M1PAM), Takeda Pharmaceutical Co. Ltd., Japan, 2020, p. 98.
 
E. T. van der Westhuizen, A. Spathis, E. Khajehali, M. Jörg, S. N. Mistry, B. Capuano, A. B. Tobin, P. M. Sexton, P. J. Scammells, C. Valant, A. Christopoulos, Mol. Pharmacol. 2018, 94, 770-783;
E. Khajehali, C. Valant, M. Jörg, A. B. Tobin, P. J. Conn, C. W. Lindsley, P. M. Sexton, P. J. Scammells, A. Christopoulos, Biochem. Pharmacol. 2018, 154, 243-254.
J. C. C. Dallagnol, E. Khajehali, E. T. van der Westhuizen, M. Jörg, C. Valant, A. G. Goncalves, B. Capuano, A. Christopoulos, P. J. Scammells, J. Med. Chem. 2018, 61, 2875-2894.
M. Jörg, E. T. van der Westhuizen, E. Khajehali, W. A. C. Burger, J. M. White, K. H. C. Choy, A. B. Tobin, P. M. Sexton, C. Valant, B. Capuano, A. Christopoulos, P. J. Scammells, ACS Chem. Neurosci. 2019, 10, 1099-1114.
L. T. May, K. Leach, P. M. Sexton, A. Christopoulos, Annu. Rev. Pharmacol. Toxicol. 2007, 47, 1-51.
 
K. Leach, P. M. Sexton, A. Christopoulos, Trends Pharmacol. Sci. 2007, 28, 382-389;
L. Aurelio, C. Valant, B. L. Flynn, P. M. Sexton, A. Christopoulos, P. J. Scammells, J. Med. Chem. 2009, 52, 4543-4547.
A. Christopoulos, Trends Pharmacol. Sci. 1998, 19, 351-357.
K. H. C. Choy, D. M. Shackleford, D. T. Malone, S. N. Mistry, R. T. Patil, P. J. Scammells, C. J. Langmead, C. Pantelis, P. M. Sexton, J. R. Lane, A. Christopoulos, J. Pharmacol. Exp. Ther. 2016, 359, 354-365.

Auteurs

Manuela Jörg (M)

Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, 3052, Victoria, Australia.

Elham Khajehali (E)

Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, 3052, Victoria, Australia.

Emma T van der Westhuizen (ET)

Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, 3052, Victoria, Australia.

K H C Choy (KH)

Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, 3052, Victoria, Australia.

David M Shackleford (DM)

Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, 3052, Victoria, Australia.

Andrew B Tobin (AB)

Centre for Translational Pharmacology, Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, G12 8QQ, UK.

Patrick M Sexton (PM)

Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, 3052, Victoria, Australia.

Celine Valant (C)

Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, 3052, Victoria, Australia.

Ben Capuano (B)

Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, 3052, Victoria, Australia.

Arthur Christopoulos (A)

Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, 3052, Victoria, Australia.

Peter J Scammells (PJ)

Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, 3052, Victoria, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH